SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lehmann Sören)
 

Sökning: WFRF:(Lehmann Sören) > (2015-2019) > Secondary Acute Mye...

  • Nilsson, ChristerKarolinska Institutet,Karolinska Institute,Karolinska Inst, Sweden (författare)

Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • Elsevier,2019
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-167012
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-167012URI
  • https://doi.org/10.1016/j.bbmt.2019.05.038DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-396629URI
  • https://lup.lub.lu.se/record/407e42e2-4bf7-4f38-a474-7f8c8e5eec69URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:142065096URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-161413URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Swedish Cancer Foundation; Stockholm County CouncilStockholm County Council; Gothenburg Medical Society; Assar Gabrielsson Foundation; Swedish Research CouncilSwedish Research Council
  • Secondary AML (s-AML), including AML with an antecedent hematologic disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of patients with AML and is considered to confer a dismal prognosis. The role of allogeneic hematopoietic cell transplantation (HCT) in patients with s-AML and the extent to which HCT is performed in these patients has been little studied to date. We used the population-based Swedish AML Registry comprising 3337 intensively treated adult patients over a 17-year period to study the role of HCT within the group of patients with s-AML as well as compared with patients with de novo AML. HCT was performed in 576 patients (22%) with de novo AML, in 74 patients (17%) with AHD-AML, and in 57 patients (20%) with t-AML. At 5 years after diagnosis, there were no survivors among patients with previous myeloproliferative neoplasms who did not undergo HCT, and corresponding survival for patients with antecedent myelodysplastic syndromes and t-AML was and 2% and 4%, respectively. HCT was compared with chemotherapy consolidation in s-AML using 3 models: (1) a 200-day landmark analysis, in which HCT was favorable compared with conventional consolidation (P = .04, log-rank test); (2) a multivariable Cox regression with HCT as a time-dependent variable, in which the hazard ratio for mortality was 0.73 (95% confidence interval, 0.64 to 0.83) for HCT and favored HCT in all subgroups; and (3) a propensity score matching analysis, in which the 5-year overall survival (OS) and relapse-free survival in patients with s-AML in first complete remission (CR1) was 48% and 43%, respectively, for patients undergoing HCT versus 20% and 21%, respectively, for those receiving chemotherapy consolidation (P = .01 and .02, respectively, log-rank test). Our observational data suggest that HCT improves survival and offers the only realistic curative treatment option in patients with s-AML. 

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hulegårdh, ErikSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital (författare)
  • Garelius, HegeSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital (författare)
  • Möllgård, LarsSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital (författare)
  • Brune, MatsSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital (författare)
  • Wahlin, AndersUmeå University,Umeå universitet,Onkologi,Univ Umea, Dept Radiat Sci, Umea, Sweden(Swepub:umu)anwa0027 (författare)
  • Lenhoff, StigLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden(Swepub:lu)med-slf (författare)
  • Frödin, UllaLinköpings universitet,Linköping University,Institutionen för medicin och hälsa,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US(Swepub:liu)n/a (författare)
  • Remberger, MatsKarolinska Inst, Dept Oncol Pathol, Stockholm, Sweden,Karolinska University Hospital (författare)
  • Höglund, MartinUppsala University,Uppsala universitet,Hematologi,Uppsala Univ, Sweden(Swepub:uu)martinhl (författare)
  • Juliusson, GunnarLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Lund Univ, Sweden(Swepub:lu)stem-gju (författare)
  • Stockelberg, DickSodra Alvsborgs Hosp, Dept Med & Oncol, Boras, Sweden,South Elfsborg Hospital (författare)
  • Lehmann, SörenKarolinska Institutet,Uppsala University,Karolinska Institute,Karolinska Inst, Sweden; Uppsala Univ, Sweden (författare)
  • Karolinska InstitutetKarolinska Institute (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Biology of blood and marrow transplantation: Elsevier25:9, s. 1770-17781083-87911523-6536

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy